OCS · Oculis Holding AG
Market Cap
$678.00M
Shares
55.53M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.25
Open$12.11
Day$11.99–12.34
52W close$10.71–32.65
Avg vol 30d253K
Short int1.5M · 2.6% float · 5.3d
Short vol28%
Last earningsNov 5, 2026
DataMay 2021–Aug 2026
Up next
Next earnings call
Nov 5, 2026
Scheduled
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−2%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−57%
trailing
YTD return
−39%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $21 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.63% of float · ▼ -0.0% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
65 holders — near 3-yr high, broad support
Squeeze score
48
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $21 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +21 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.63% of float · ▼ -0.0% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
65 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $12 · 7%
Range high $33
vs 200-day avg -42%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCS
this stock
Oculis Holding AG
|
$678.00M | -38.7% | — | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCS | -7.1% | +3.0% | -57.2% | +8.3% | -38.7% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -7.5% | +1.8% | -70.5% | +5.6% | -51.1% |
Key facts
CIK
1953530
CUSIP
H5870P102
13F (30d)
58 filings
58 filers
Visit website
Investor relations